Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Part of paid clinical trials in Augusta, Georgia.

Sponsor
Augusta University
Study ID
NCT04449198
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Resveratrol — DRUG
    500 mg of oral trans-resveratrol twice daily (in the morning and evening) for 12-weeks
  • Placebo — OTHER
    placebo for 12 weeks

Study Details

The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.

Key Dates

Start date
Oct 14, 2020
Status verified
Jan 2025
Primary completion
Jan 1, 2027
Completion
Jul 1, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Individuals with type 1 diabetes
    Individuals with type 1 diabetes will be randomly assigned to 1 of the 2 interventions (Resveratrol or placebo)
  • No Intervention: Healthy Controls
    Healthy individuals who participate will receive no intervention and serve as controls.

Primary Outcome Measure

Change in AUC for ET-1 + BQ-123 [ Time Frame: Measure taken at Baseline and post 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise PhysiologyAugustaGeorgia30912
Ryan Harris, PhD, CEP
[email protected]
706-721-5998
Casey Derella, BS
[email protected]
706-721-5483

Find similar trials in Augusta, GA

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology· Augusta, GA

Related Studies